I-BET762 growth IC50 against myeloma cell lines as assessed after 72 hours of treatment with varying concentrations of I-BET762
| Cell line* . | Primary genetic lesion . | Growth IC50 (nM) . |
|---|---|---|
| LP-1 | t(4;14) | 46.35 |
| JJN-3 | t(14;16) | 56.55 |
| OPM-2 | t(4;14) | 60.15 |
| H929 | t(4;14) | 71.85 |
| MM.1S | t(14;16) | 131.95 |
| KMS11 | t(4;14) | 142.3 |
| RPMI8266 | t(16;22) | 195.1 |
| RPMI8266 MR20 | t(16;22) | 535.1 |
| KMS12BM | semi-cryptic t(11;14) | 578.45 |
| MM.1R | t(14;16) | 756.25 |
| U266B1 | t(11;14) | 1056.8 |
| RPMI8266 LR5 | t(16;22) | 1487.8 |
| L-363 | t(11;14) | 1985.5 |
| RPMI8266 DOX 40 | t(16;22) | 7244.3 |
| Cell line* . | Primary genetic lesion . | Growth IC50 (nM) . |
|---|---|---|
| LP-1 | t(4;14) | 46.35 |
| JJN-3 | t(14;16) | 56.55 |
| OPM-2 | t(4;14) | 60.15 |
| H929 | t(4;14) | 71.85 |
| MM.1S | t(14;16) | 131.95 |
| KMS11 | t(4;14) | 142.3 |
| RPMI8266 | t(16;22) | 195.1 |
| RPMI8266 MR20 | t(16;22) | 535.1 |
| KMS12BM | semi-cryptic t(11;14) | 578.45 |
| MM.1R | t(14;16) | 756.25 |
| U266B1 | t(11;14) | 1056.8 |
| RPMI8266 LR5 | t(16;22) | 1487.8 |
| L-363 | t(11;14) | 1985.5 |
| RPMI8266 DOX 40 | t(16;22) | 7244.3 |
Treatment-sensitive MM.1S and RPMI8226 cell lines, treatment-resistant MM.1R (dexamethasone resistant), RPMI8266 MR40 (mitoxantrone resistant), RPMI8266 DOX40 (doxorubicin resistant), and RPMI8266 LR5 (melphalan resistant).